HIPEC Treatment for Appendix Cancer
HIPEC is a common therapy for appendix cancer!
HIPEC has become a common treatment therapy for the treatment of Appendix Cancer.
What is HIPEC?
Hyperthermic intraperitoneal chemotherapy, or HIPEC, is a procedure in which heated chemotherapy is circulated within the abdomen. The chemotherapy(ies) (most commonly Mitomycin C or Mitomycin C plus Oxaliplatin) are heated to 42°C or 107.6°F with the goal of killing any hidden tumor cells. HIPEC includes the use of a heated sterile solution with chemotherapy continuously circulated throughout the abdominal cavity for approximately 90 minutes.
HIPEC treatment provides surgeons with the ability to apply high doses of chemotherapy directly into the peritoneal cavity without significant toxicity to the remainder of the body. The effects of heat with regionally applied chemotherapy, may increase the efficacy of the treatment, with the goal of achieving a cure. The HIPEC treatment is applied directly following peritonectomy or CRS (cytoreductive surgery.)
HIPEC is also referred to as perfusion. HIPEC involves perfusion of the peritoneal cavity.
HIPEC may be included at the conclusion of the cytoreductive surgery for the treatment of pseudomyxoma peritonei and appendix cancer if substantial tumor debulking is accomplished through CRS. HIPEC may be administered when complete removal of visible tumor (or debulking) is achieved through cytoreductive surgery; it involves perfusion of the peritoneal cavity with chemotherapy heated to approximately 40 degrees Celsius.
HIPEC is administered with the infusion of heated chemotherapy during the last 90 minutes of the CRS procedure. Through HIPEC the surgeon(s) intend to destroy any residual tumor cells that may not have been surgically removed during the actual CRS surgery process.
Although this procedure may initially sound drastic to the newly diagnosed patient, rarely is resection and/or removal of all of these organs is required. Each patient's case is unique and most patients live productive and healthy lives following surgery!
Refer to our surgeons and specialists page for an international listing of HIPEC treatment providers.
Where can I talk with other HIPEC patients?
Want to learn more about preparing for and recuperating from HIPEC?
Join the PMP Pals' Network HIPEC Pals' Resource Group today!
Free help for HIPEC insurance "issues!"
Who are the appendix cancer HIPEC treatment specialists?
Click on any of the following website links to read more about HIPEC treatment:
Pros and Cons of HIPEC: Need for Phase III Trials
Source: Oncology Times, January 2007
International Consensus of PSMG for CRS and HIPEC
Source: Springerlink, Oct 2006
AUSTRALIA
St George's Hospital, Sydney
Morbidity and Mortality: Study of HIPEC and CRS for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgery, Feb 2009, Dr David Morris, Dr Tristan Yan
BELGIUM
Dr Stefaan Mulier provides HIPEC treatment for Pseudomyxoma Peritonei and Peritoneal Carcinomatosis
Source: Leopold Park Clinic in Brussels
Dr Wim P Ceelen, MD, PhD, FACS treats Pseudomyxoma Peritonei with HIPEC www.surgery.ugent.be
CANADA
Treatment of Peritoneal Carcinomatosis
Source: Universite de Montreal, Canada, 2009
FRANCE
Treatment for Pseudomyxoma Peritonei
Source: Institut Gustave Roussy, Cedex 2008
GERMANY
HIPEC treatment related articles...
Safety of Gastric Resection During Cytoreductive Surgery Source: Annals of Surgical Oncology, 2009, Prof P Piso
Quality of life following surgery for Peritoneal Carcinomatosis
Source: Dr Pompiliu Piso, 2009
CRS and HIPEC for the Treatment of Peritoneal Carcinomatosis
Source: Prof Pompiliu Piso, 3rd Annual Symposium, 2008
CRS for Senior Patients
Source: Dr Herwart Mueller, Germany
Peritoneal Carcinomatosis
Source: University of Erlangen Nuremberg 2006
Improved Prognosis for Pseudomyxoma Peritonei and Appendix Cancer
Source: German Medical Science, 2006
Study with laboratory rats
Source: Deutscher Krebskongress, 2004
PHASE II STUDY FOR PERITONEAL CARCINOMATOSIS
Professor P Piso, in Regensburg, Germany provides a prospective, multicenter Phase II study evaluating multimodality treatment with pre- and postoperative systemic chemotherapy with FOLFOX/Cetuximab or FOLFIRI/ Cetuximab, complete cytoreductive surgery (CRS), and HIPEC in patients with diagnosed with Peritoneal Carcinomatosis.
For more information and to contribute to Prof Piso's research, contact him via:
Leitender Oberarzt
Klinik und Poliklinik für Chirurgie
der Universität Regensburg
Franz Josef Strauß Allee 11
D-93053 Regensburg
Tel.:0941-944-6809
Fax:0941-944-6860
Source: Dr Piso provided this information to the PMP Pals' Network.
GREECE
Antonios-Apostolos K Tentes, M.D. Director of the Surgical Department at the Didimotichon General Hospital in Didmotichon Greece is conducting several clinical trials including one focused on colorectal cancer and one focused on gastric cancer.
Colorectal Cancer: This study focuses on patients with colorectal cancer who have T3 and T4 tumors. The patients are randomly selected to undergo either surgery alone, or surgery combined with HIPEC, provided that R0 resection has been performed. The final goal of the study is compare the survival rates between these two groups of patients.
Gastric Cancer: This study includes patients with T3 and T4 tumors. The patients undergo D2 gastrectomies and receive HIPEC.
No further treatment is required. The goal of this study is to identify the survival and recurrence rates.
For more information, contact:
Dr Atonios-Apostolos K Tentes
Didimotichon General Hospital
Didimotichon, 68300, Greece
ITALY
Twelve year study of Pseudomyxoma Peritonei Treatment with CRS and HIPEC
Source: San Giuseppe Hospital, June 2009
Prognosis for Pseudomyxoma Peritonei following surgery
Source: NCI, Milan, Italy 2009
Prognosis for Pseudomyxoma Peritonei evaluating tumor markers following surgery
HIPEC Treatment: Dott. Marcello Deraco: Pseudomyxoma Peritonei and Appendix Cancer
Source: Dott. Marcello Deraco
JAPAN
Treatment of Appendix Cancer and Pseudomyxoma Peritonei
Source: Pub Med 2009
NEDERLAND/HOLLAND
Peritoneal Carcinomatosis, Peritoneal Carcinomatosis and Appendix Cancer in Holland
Cytoreduction and HIPEC Treatment for Appendix Cancer and Pseudomyxoma Peritonei (pdf)
Source: Netherlands Cancer Institute, Prof VJ Verwaal, 2006
USA
HIPEC: UPMC Koch Cancer Treatment Center Pgh PA
Source: UPMC Koch Cancer Treatment Center
HIPEC: The Complexity of Clinical Trials
Source: Dr David L Bartlett, UPMC, Society of Surgical Oncology 2008
CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgial Oncology, Nov 2008
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annuals of Surgical Oncology, 2008
Treatment and Definition for the Treatment of Pseudomyxoma Peritonei and Appendix Cancer
Source: University of Maryland
Dr Martin Goodman provides HIPEC
Source: Tufts, Boston
Dr Perry Shen: Pseudomyxoma Peritonei and Appendix Cancer Treatment
Source: Dr Perry Shen, WFU
DPAM and and HIPEC Treatment
Source: Wake Forest University
Dr David L Bartlett; HIPEC Complexity
Source: Society of Surgical Oncology
Koch Cancer Center (Drs David L Bartlett, James Pingpank, Matthew Holtzman, S. Ahrendt)
Source: UPMC Koch Cancer Center
Dr Martin Goodman:Pseudomyxoma Peritonei and Appendix Cancer Treatment
Source: Tufts 2009
Dr Andrew Lowy: Pseudomyxoma Peritonei andAppendix Cancer
http://health.ucsd.edu/cancer/patcare/gastro/appendiceal/
Dr Jesus Esquivel: HIPEC Treatment
HIPEC Treatment with Graph Description
Source:Dr Jesus Esquivel HIPEC.org
Dr Jesus Esquivel: Pseudomyxoma Peritonei and Appendix Cancer Treatment
Source: Dr Jesus Esquivel, St Agnes
Pros and Cons of HIPEC: Dr Jesus Esquivel
Source: Oncology Times, Jan 2007
Dr Armando Sardi:CRS and HIPEC offer longterm survival for Peritoneal Carcinomatosis of disseminated Appendiceal tumor origin
Source: Dr Armando Sardi, Mercy Med Center, Journal of American College of Surgeons, Sept 2009
Dr Paul Sugarbaker evaluates perioperative chemotherapy agents for treatment of Pseudomyxoma Peritonei
Source: The Oncolgist, Feb 2005
ASCO Summaries for post op prognosis of Pseudomyxoma Peritonei
Source: ASCO
Phase I Study for Appendix Cancer
Source: NIC and WFU, 2009
HIPEC for Pseudomyxoma Peritonei and Peritoneal Carcinomatosis Treatment
Surgery with HIPEC (pdf)
HIPEC for OB/GYN
HIPEC: Intraoperative HIPEC Treatment w/Cisplatin for Peritoneal Carcinomatosis of Ovarian Origin
Health Insurance Coverage for HIPEC
Insurance and Appeals assistance for HIPEC coverage of payment
Source: ThermaSolutions, Inc.
See Health Insurance
Medicare "code" for HIPEC treatment: 96445
Appeals for Insurance Denials
How to Appeal a Denial from your Health Insurance Provider (including denials for HIPEC treatment)
HIPEC Video
HIPEC Video: Intraperitoneal Hyperthermic Perfusion
This video includes graphic scenes of surgery being peformed.
Source:You Tube: Perfusion Network, National Cancer Institute of Milan, Italy
International consensus statement regarding HIPEC
HIPEC Consensus Statement 2006
Source: Springerlink 2006
Legal and Safety Considerations for HIPEC Administration
Legal and Safety Considerations of Administering HIPEC, Risk/Benefit Analysis for HIPEC, Morbidity-Mortality, Protection of Medical Personell During Administration of HIPEC, Biohazard Management of HIPEC, OSHA, NOSH, Certification
Source: Centre Hospitalier Lyon Sud, Pierre Benite, France, 2008
HIPEC, General Interest for Appendix Cancer, Peritoneal Carcinomatosis and Pseudomyxoma Peritonei Patients
Terumo Medical Corporation
Manufacturerer of HIPEC perfusion equipment
Visitors to www.pmppals.org are encouraged to discuss publications and information contained herein with their licensed, professional healthcare providers. The information provided on www.pmppals.org is not intended as a replacement for licensed, professional medical or legal advice.
Please respect your fellow patients and caregivers by not copying or cutting and pasting any pages from this website onto yours.
The PMP Pals Network is a volunteer patient advocacy program. We support the services that we provide, including this web page, as volunteers and through subscriptions to our publications.
We neither solicit nor receive funds from pharmaceutical companies or healthcare providers, thus maintaining our dedication to serving as patient advocates.Updated 01.25.12